LIFT: Sodium zirconium cyclosilicate doubled the share of HFrEF patients with CKD reaching target RAASi dose without hyperkalemia (2026) — Trial Summary

LIFT: Sodium zirconium cyclosilicate doubled the share of HFrEF patients with CKD reaching target RAASi dose without hyperkalemia (2026): Double-blind, placebo-controlled randomized trial in patients with heart failure with reduced ejection fraction, CKD stages 3-5, and serum potassium 5.0 to 5.5 mm

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.